Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Imunon, Inc. (IMNN) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $14.85 per share as of 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-03-31
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $14.85; Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed $0.99.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $18.45; Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed $1.23.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $1.92.
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $12.36; Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed $14.25.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed |
|---|---|---|
| 2024-12-31 | $14.85 10-K · filed 2026-03-31 | $0.99 10-K · filed 2025-02-27 |
| 2023-12-31 | $18.45 10-K · filed 2026-03-31 | $1.23 10-K · filed 2024-03-28 |
| 2022-12-31 | $1.92 10-K · filed 2025-02-27 | |
| 2021-12-31 | $12.36 10-K · filed 2024-03-28 | $14.25 10-K · filed 2022-03-31 |
| 2020-12-31 | $9.45 10-K · filed 2023-03-30 | $0.98 10-K · filed 2021-03-19 |
| 2019-12-31 | $23.85 10-K · filed 2022-03-31 | $1.59 10-K · filed 2021-03-19 |
| 2019-03-31 | $3.08 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $2.72 10-K · filed 2021-03-19 | $5.36 10-Q · filed 2019-05-15 |
| 2016-12-31 | $2.67 10-K · filed 2017-03-24 | |
| 2015-12-31 | $2.64 10-K · filed 2017-03-24 | |
| 2014-12-31 | $3.32 10-K · filed 2017-03-24 | |
| 2014-06-30 | $3.54 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $4.63 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $14.13 10-K · filed 2016-03-30 | $16.29 10-Q · filed 2014-05-08 |
| 2013-09-30 | $13.64 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $3.03 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $3.20 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $14.63 10-K · filed 2016-03-30 | $3.20 10-Q · filed 2013-05-09 |
| 2012-09-30 | $3.13 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $3.08 10-Q · filed 2012-08-14 | |
| 2011-12-31 | $14.22 10-K · filed 2015-03-12 | $3.16 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |